Classification,Treatment Goals,and Management Principles for Myelodysplasic Syndromes

Verbeek W. , Ganser A. Evolving treatment options of myelodysplastic syndromes. Ann Hematol. 2001; 80: 499–509.

Steensma D.P. , Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003; 27: 95–120.

van Dijk J.P. , de Witte T. Monitoring treatment efficiency in MDS at the molecular level: possibilities now and in the future. Leuk Res. 2004; 28: 101–108.

Bennett J.M. , Catovsky D. , Daniel M.T. Proposals for the classification of the acute leukaemias: French-American-British (FAB) cooperative group. Br J Haematol. 1976; 33: 451–458.

Bennett J.M. , Catovsky D. , Daniel M.T. Proposals for the classification of myelodysplastic syndromes. Br J Haematol. 1982; 51: 189–199.

Bennett J.M. , Brunning R.D. , Vardiman J.W. Myelodysplastic syndromes: from French-American-British to World Health Organization. A commentary. Blood. 2002; 99: 3074–3075.

Bennett J.M. , Catovsky D. , Daniel M.T. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol. 1991; 78: 325–329.

Bennett J.M. , Catovsky D. , Daniel M.T. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103: 620–625.

Valent P. , Wimazal F. , Schwarzinger I. Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). Wien Klin Wochenschr. 2003; 115: 515–536.

Bennett J.M. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol. 2000; 72: 131–133.

Greenberg P. , Cox C. , LeBeau M.M. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079–2088.

Balduini C.L. , Guarnone R. , Pecci A. International prognostic scoring system and other prognostic systems for myelodysplastic syndromes. Blood. 1997; 90: 4232–4234.

Sanz G.F. , Sanz M.A. , Greenberg P.L. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998; 83: 358–368.

Greenberg P.L. , Young N.S. , Gattermann N. Myelodysplastic syndromes. Hematology. 2002; 136–161.

Cheson B.D. , Bennett J.M. , Kantarjian H. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 3671–3674.

Deeg H.J. , Guardiola P. Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. Int J Hematol. 2002; 76(suppl 2): 2934.

Cheson B.D. , Zwiebel J.A. , Dancey J. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol. 2000; 27: 560–577.

Silverman L.R. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist. 2001; 6(suppl 5): 8–14.

Thomas M.L. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res. 1998; 22(suppl 1): S41–S47.

Kemmler G. , Holzner B. , Kopp M. Multidimensional scaling as a tool for analysing quality of life data. Qual Life Res. 2002; 11: 223–233.